Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in a fireside chat as part of the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3 at 9:50 a.m. ET.

GlobeNewsWire • 3 hours ago

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026

REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, February 25, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress.

GlobeNewsWire • Feb 18, 2026

Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Seeking Alpha • Feb 11, 2026

Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026

REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A.

GlobeNewsWire • Feb 4, 2026

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability to convert a strong backlog and increasingly sophisticated project mix into sustained earnings growth. We did not make any adjustments to the position and continue to believe that the market opportunity remains robust.

Seeking Alpha • Jan 30, 2026

RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer

Revolution Medicines stock tanks after a WSJ report said Merck has withdrawn from buyout talks over price.

Zacks Investment Research • Jan 27, 2026

Why Revolution Medicines Stock Plummeted by Almost 17% Today

An apparent suitor has withdrawn from talks about acquiring the biotech, according to a media report. That's particularly discouraging, given that this business was apparently discussing a deal in the tens of billions of dollars for Revolution.

The Motley Fool • Jan 27, 2026

Revolution Medicines Stock Sinks After Merck Deal Talks Collapse

Merck & Co., Inc. (NYSE: MRK) has reportedly ended discussions to acquire cancer drug developer Revolution Medicines, Inc. (NASDAQ: RVMD) after the two sides disagreed on valuation.

Benzinga • Jan 26, 2026

Overlooked Stock: RVMD Sells After MRK Turns Away

Revolution Medicines (RVMD) reversed a lot of its recent rally on Monday after the Wall Street Journal reported that Merck (MRK) is no longer looking to buy the biotech firm. However, as George Tsilis explains, there may be more pressure pinning the stock beyond its potential missed acquisition story.

Merck no longer in talks to buy Revolution Medicines, WSJ reports

Merck is no longer in discussions to buy cancer drug developer Revolution Medicines , the Wall Street Journal reported on Sunday.

Reuters • Jan 25, 2026